Fibrinogen, Lp(a), Microalbuminuria and Left Ventricular Mass Index: Cardiovascular Disease Risk factors in Diabetes

Abstract

The present work was undertaken to study interrelation of Fibrinogen, Lp(a) and LVMI in Type II diabetes patients with or without nephropathy. 100 Type II Diabetic patients attending OPD/IPD of DMC&H, Ludhiana were included. They were divided in two groups. Group I: 50 patients without microalbuminuria (MAU). Group II: 50 patients with MAU. Fibrinogen (Clauss method), Lp(a) and MAU were estimated on Multichannel Autoanalyzer Hitachi-911 (Roche). LVMI was estimated by echocardiography using formula of Devereux and Reicheck. Type II diabetes patients with MAU had significantly raised levels of Fibrinogen, Lp(a), and LVMI as compared to normoalbuminuric diabetics (P \ 0.01). Group II patients had positive correlation between Lp(a) and LVMI but no relation between Fibrinogen and LVMI. MAU, marker of microangiopathy, is associated with higher Fibrinogen and Lp(a) levels. This becomes basis of increase cardiovascular risk as demonstrated by higher mean LVMI in Group II patients.

Effects of Coenzyme Q10 Supplementation on Serum Lipoproteins, Plasma Fibrinogen, and Blood Pressure in Patients With Hyperlipidemia and Myocardial Infarction

“…On the other hand, it stimulates platelet aggregation in vessels by launching occlusive arterial blood clot ( 20 ). As elevated concentration of fibrinogen increases blood viscosity and slows blood flow, it causes thrombus formation considerably ( 21 ). The great amounts of HDL-C raises fibrinolysis and inhibits platelet aggregation and LDL-C oxidation ( 22 ).…”

Cardiovascular Risk Detection Through Big Data Analysis

“…protein(CRP)andhomocysteine(Cheng,Tu,Shen,Zhang&Ji,2018),fibrinogen(Kaur, Singh, Indu, & Singla, 2012), homocysteine and lipoprotein-associated phospholipase 2 (Lp-PLA 2 )(Nicholls,2018);…”

Metabolismo de lípidos y disfunción endotelial en pacientes diabéticos tipo 2 tratados con insulina o hipoglucemiantes orales

“…Desde hace unos seis años se conocen las propiedades antiinflamatorias de la insulina y el efecto restaurador de la dislipemia como así también su acción normalizadora del cociente Ox-LDL/C-LDL en pacientes DM2 (Galland et al, 2008). Todos estos beneficios se observaron claramente a través de nuestras determinaciones de los biomarcadores de metabolismo lipídico y riesgo aterogénico, pero quizás de manera mas importante para marcadores emergentes o no tradicionales como el cociente Apo-B100/Apo-A1 y triglicéridos/C-HDL que, junto con el nivel de Lp(a), se los considera últimamente como los principales índices con elevada capacidad predictiva o evolutiva de riesgo cardiovascular en DM2 (Gómez et al, 2009;Kaur et, 2012;Qui y Qui, 2012;Kadoglou et al, 2012;Gazzaruso et al, 2012).…”